Boston Scientific Revenue decreased by 1.6% to $5.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.6%, from $4.66B to $5.20B. Over 4 years (FY 2021 to FY 2025), Revenue shows an upward trend with a 14.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growth in market share or higher demand, while a decrease may signal market saturation or competitive pressure.
Represents the total consideration received from customers for the sale of goods or services, excluding any sales-relate...
Standard across all public companies; comparable to 'Net Sales' or 'Total Revenue' at peer distributors.
other_revenue_from_contract_with_customer_excluding_asse_0d5b70| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.08B | $2.93B | $3.13B | $3.03B | $3.24B | $3.17B | $3.24B | $3.39B | $3.60B | $3.53B | $3.73B | $3.86B | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
| QoQ Change | — | -4.7% | +6.7% | -3.2% | +7.2% | -2.3% | +2.3% | +4.5% | +6.2% | -2.0% | +5.6% | +3.5% | +6.8% | +2.2% | +8.4% | +2.2% | +8.5% | +0.1% | +4.4% | -1.6% |
| YoY Change | — | — | — | — | +5.4% | +8.1% | +3.7% | +12.0% | +10.9% | +11.3% | +14.9% | +13.8% | +14.5% | +19.3% | +22.4% | +20.9% | +22.8% | +20.3% | +15.9% | +11.6% |